Vilazodone, levomilnacipran and vortioxetine for major depressive disorder: The 15-min challenge to sort these agents out

International Journal of Clinical Practice

Volumn 69, Issue 2, 2015, Pages 151-155

  Citrome, L ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; KETOCONAZOLE; LINEZOLID; METHYLENE BLUE; MILNACIPRAN; MONOAMINE OXIDASE INHIBITOR; PLACEBO; VILAZODONE; VORTIOXETINE; CYCLOPROPANE DERIVATIVE; PIPERAZINE DERIVATIVE; SULFIDE;

ANTIDEPRESSANT ACTIVITY; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DIARRHEA; DOSE RESPONSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG INFORMATION; DRUG MECHANISM; DRUG MONITORING; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; ERECTILE DYSFUNCTION; HEALTH CARE MANAGEMENT; HEART PALPITATION; HEART RATE; HIGH RISK PATIENT; HUMAN; HYPERHIDROSIS; HYPERSENSITIVITY; INSOMNIA; LIKELIHOOD TO BE HELPED OR HARMED; MAJOR DEPRESSION; MEAL; MONGOMETRY ASBERG DEPRESSION RATING SCALE; NAUSEA; NUMBER NEEDED TO HARM; NUMBER NEEDED TO TREAT; OUTCOME ASSESSMENT; PREVALENCE; PSYCHOMETRY; RATING SCALE; RECOMMENDED DRUG DOSE; REMISSION; SEXUAL FUNCTION; SIDE EFFECT; SUICIDE; TACHYCARDIA; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT RESPONSE; UNITED STATES; VOMITING; DEPRESSIVE DISORDER, MAJOR;

ANTIDEPRESSIVE AGENTS; CYCLOPROPANES; DEPRESSIVE DISORDER, MAJOR; HUMANS; PIPERAZINES; SULFIDES; VILAZODONE HYDROCHLORIDE;

EID: 84921716481     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12620     Document Type: Editorial

References (15)

1. Citrome L,. Lorcaserin, phentermine topiramate combination, and naltrexone bupropion combination for weight loss: the 15-min challenge to sort these agents out. Int J Clin Pract 2014; 68: 1401-5.
2. Gelenberg AJ, Freeman MP, Markowitz JC, et al. Practice Guideline for the Treatment of Patients with Major Depressive Disorder, 3rd edn. Arlington, VA: American Psychiatric Association, 2010.
3. Citrome L,. Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant-what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 2012; 66: 356-68.
4. Citrome L,. Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant-what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 2013; 67: 1089-104.
5. Citrome L,. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant-what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 2014; 68: 60-82.
6. Forest. VIIBRYD (Vilazodone HCl) Tablets for Oral Administration. Prescribing information. Revised July 2014. http://pi.actavis.com/data
7. Forest. FETZIMA (Levomilnacipran) Extended-Release Capsules, for Oral Use. Prescribing information. Revised July 2014. http://pi.actavis.com/data
8. Takeda. BRINTELLIX (Vortioxetine) Tablets, for Oral Use. Prescribing information. Revised July 2014. http://us.brintellix.com/ (accessed 20 December 2014).
9. Popova NK, Naumenko VS,. 5-HT1A receptor as a key player in the brain 5-HT system. Rev Neurosci 2013; 24: 191-204.
10. Rajkumar R, Mahesh R,. The auspicious role of the 5-HT3 receptor in depression: a probable neuronal target? J Psychopharmacol 2010; 24: 455-69.
11. Citrome L, Gommoll CP, Tang X, Nunez R, Mathews M,. Evaluating the efficacy of vilazodone in achieving remission in patients with major depressive disorder: post-hoc analyses of a phase IV trial. Int Clin Psychopharmacol 2014; Nov 13. [Epub ahead of print].
12. Citrome L, Ketter TA,. When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Int J Clin Pract 2013; 67: 407-11.
13. McIntyre RS, Lophaven S, Olsen CK,. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol 2014; 17: 1557-67.
14. Blier P, Briley M,. The noradrenergic symptom cluster: clinical expression and neuropharmacology. Neuropsychiatr Dis Treat 2011; 7 (Suppl. 1): 15-20.
15. Kasper S, Meshkat D, Kutzelnigg A,. Improvement of the noradrenergic symptom cluster following treatment with milnacipran. Neuropsychiatr Dis Treat 2011; 7 (Suppl. 1): 21-7.